Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00544895

Acronym

NEOBRAIN

Enrollment

600

Registered

2007-10-16

Start date

2007-10-31

Completion date

2010-10-31

Last updated

2011-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Damage, Chronic

Brief summary

NEOBRAIN brings together small and medium sized enterprises (SMEs), industry and academic groups devoted to the diagnosis, management, and neuroprotection in newborns with perinatal brain damage. The focus of NEOBRAIN is to identify strategies prevention of brain damage mainly observed in preterm newborns. (Copy from www.neobrain.eu)

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Gestational age \< 28 weeks

Design outcomes

Primary

Measure	Time frame
Brain white matter damage (WMD, defined by MRI ,US, EEG)	during stay in NICU and until discharge

Secondary

Measure	Time frame
Developmental assessment	at 2 years of age

Countries

Austria, France, Germany, Italy, Netherlands, Sweden, Switzerland

Outcome results